Fuwai Hospital
Beijing, China
NCT Number: NCT07045233
After more than a decade of development, transcatheter aortic valve replacement (TAVR) is now a standard, guideline-recommended treatment for all symptomatic patients with severe aortic stenosis, regardless of their surgical risk. However, stroke remains a risk for these patients after TAVR. Given its severe impact-significantly increasing post-procedure mortality and severely affecting quality of life-preventing TAVR-related stroke is an urgent problem we need to solve.
The Sentinel Cerebral Protection Device is a percutaneous dual-filter brain protection system. During the procedure, the Sentinel device's filters capture blood clots and tissue debris. After the operation, the captured clots and debris are removed from the body along with the device. Its safety and effectiveness have been validated. Therefore, this project plans to conduct a multi-center registry clinical study to:
Develop a widespread neurological risk prediction model. Create a strict, standardized prevention protocol. Boost awareness of perioperative stroke prevention during TAVR. Provide practical clinical experience. By doing so, we aim to better prevent strokes in patients undergoing TAVR.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Beijing, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
History of previous open-chest surgery or previous heart valve replacement. Patients with left ventricular ejection fraction ≤ 30%. Presence of contraindications for MRI examination. Patients with claustrophobia. Patients unable to comply with follow-up.
Deploy a Sentinel cerebral protection device during TAVR for patient with aortic stenosis.
Patients receive head MRI before and after the surgery in order to determine the stroke incidence.
Time frame: From enrollment to 72 hours post surgery or discharge (whichever comes first)
All stroke (hemorrhagic, ischemic, or undetermined status; disabling or nondisabling) through 72 hours post TAVR procedure or discharge (whichever comes first), as adjudicated by an independent Clinical Events Committee (CEC) and using Neurologic Academic Research Consortium (NeuroARC) definitions.
China National Center for Cardiovascular Diseases
Other Gov
Acronym: SENTINEL-TAVR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07411664
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Kaposvár, Somogy County, Hungary
View Trial DetailsNCT07719387
Brain Diseases, Cardiovascular Diseases
Stony Brook, New York, United States
View Trial DetailsNCT07681102
Brain Diseases, Cardiovascular Diseases
Berkeley, California, United States
View Trial DetailsNCT04534556
Brain Diseases, Cardiovascular Diseases
Dallas, Texas, United States
View Trial Details